This product is hydrolyzed into benazeprilat in the liver, becoming a competitive angiotensin converting enzyme inhibitor, preventing angiotensin I from converting to angiotensin II, reducing vascular resistance, reducing aldosterone secretion, and increasing plasma renin activity. Benazeprilat also inhibits the degradation of bradykinin, which also reduces vascular resistance and produces a hypotensive effect. In addition, this product dilates arteries and veins, reduces peripheral vascular resistance or cardiac afterload, reduces pulmonary capillary entrapment pressure or cardiac preload, and also reduces pulmonary vascular resistance, thereby improving cardiac output and prolonging exercise tolerance and time.

This product is a prodrug, which is hydrolyzed into the active substance benazeprilat, which can inhibit angiotensin converting enzyme (ACE) and prevent angiotensin I from converting into angiotensin II, thereby reducing vasoconstriction and the production of aldosterone. By inhibiting kininase and reducing the degradation of bradykinin, it helps to improve the antihypertensive effect. It is used to treat hypertension, congestive heart failure and progressive chronic renal insufficiency.

This product is a non-sedating, long-acting tricyclic antihistamine and an active metabolite of loratadine. It can relieve symptoms related to allergic rhinitis or chronic idiopathic urticaria by selectively blocking peripheral H1 receptors. In addition, in vitro studies have shown that this product can inhibit the release of histamine from human mast cells. Animal studies have shown that this product is not easy to pass through the blood-brain barrier.

This product is a bisphosphonate drug. In vitro and animal tests have shown that it can strongly inhibit the dissolution of hydroxyapatite and the activity of osteoclasts, and has a very significant inhibitory effect on bone absorption. It has an analgesic effect on pain caused by osteolytic bone metastasis of cancer, and can also be used to treat hypercalcemia caused by cancer.

This product is a bisphosphonate drug. In vitro and animal tests have shown that it can strongly inhibit the dissolution of hydroxyapatite and the activity of osteoclasts, and has a very significant inhibitory effect on bone absorption. It has an analgesic effect on pain caused by osteolytic bone metastasis of cancer, and can also be used to treat hypercalcemia caused by cancer.